<DOC>
	<DOCNO>NCT01207141</DOCNO>
	<brief_summary>This open-label clinical trial evaluate pharmacodynamics , pharmacogenomics early efficacy safety steroid-free Tacrolimus ( TAC ) monotherapy minimization induction rabbit , anti-human thymocyte globulin ( rATG , Genzyme , Cambridge , MA ) child adult pediatric liver transplantation . Eighty subject ( 0-21 year ) receive liver transplantation enrol . Incidence severity biopsy-proven acute cellular rejection ( ACR ) primary endpoint well time Tacrolimus whole blood concentration &lt; 8 ng/ml The expected incidence ACR 50 % derive non-consecutive subject population ( n=40 ) receive identical regimen IND 64555 . This incidence acceptable long term sequel rejection report allograft observe liver grafts IND 64555 . These risk negate unique regenerative capacity liver allograft . An OBSERVATIONAL arm include trial . Because number pediatric liver transplant ( LTx ) small single center setting , information know relative outcome conventional protocol , child receive conventional protocol steroids+Tacrolimus . The PURPOSE additional recruitment OBSERVATIONAL , . Therefore , subject NOT randomize . Rather , study type patient , investigator hope utilize maximally , available subject , understand relative place monotherapeutic induction . In turn , basis follow-up comparative , randomize trial .</brief_summary>
	<brief_title>rATG Induction Tacrolimus Monotherapy Pediatric Liver Transplantation</brief_title>
	<detailed_description>This open-label clinical trial evaluate pharmacodynamics , pharmacogenomics early efficacy safety steroid-free Tacrolimus ( TAC ) monotherapy minimization induction rabbit , anti-human thymocyte globulin ( rATG , Genzyme , Cambridge , MA ) child adult pediatric liver transplantation . Eighty subject ( 0-21 year ) receive liver transplantation enrol . Incidence severity biopsy-proven acute cellular rejection ( ACR ) primary endpoint well time Tacrolimus whole blood concentration &lt; 8 ng/ml The expected incidence ACR 50 % derive non-consecutive subject population ( n=40 ) receive identical regimen Investigational New Drug ( IND ) 64555 . This incidence acceptable long term sequel rejection report allograft observe liver grafts IND 64555 . These risk negate unique regenerative capacity liver allograft . An OBSERVATIONAL arm include trial . Because number pediatric liver transplant ( LTx ) small single center setting , information know relative outcome conventional protocol , child receive conventional protocol steroids+Tacrolimus . The PURPOSE additional recruitment OBSERVATIONAL , . Therefore , subject NOT randomize . Rather , study type patient , hope utilize maximally , available subject , understand relative place monotherapeutic induction . In turn , basis follow-up comparative , randomize trial . The protocol also incorporate clearly define schedule minimize Tacrolimus ( TAC ) maintenance therapy subject , base presence absence early biopsy-proven rejection . Secondary clinical endpoint : 3 . Time steroid elimination . 4 . Duration steroid treatment . 5 . Steroid-resistant rejection . 6 . Cytomegalovirus ( CMV ) antigenemia ( pp5 ) CMV disease 7 . Epstein-barr virus ( EBV ) viremia 8 . Post-transplant lymphoproliferative disorder ( PTLD ) 9 . Frequency use Non-immunosuppressive co-medications - antihypertensive , magnesium bicarbonate supplement , hypokalemic agent ( safety endpoint ) . 10 . Time first rejection Secondary pharmacodynamic pharmacogenomic endpoint 1 . Longitudinal evaluation peripheral lymphocyte subset prior 1 , 4 , 12 month liver transplantation . This establish pattern lymphocyte reconstitution depletion rATG . 2 . Inheritance disequilibrium 100,000 single nucleotide polymorphism major histocompatibility region . This entail pre-transplant characterization single-nucleotide polymorphism ( SNPs ) child biological parent . Preliminary study lead u expect identification outcome-specific pattern inheritance SNPs . Such pattern could use future study allocate appropriate treatment child base predict risk rejection . For example , predict rejector could receive steroid rATG+Tacrolimus , non-rejector could avoid steroid completely . Research Design Methods : Study type : This prospective , open-label , evaluation steroid-free , induction immunosuppression child receive liver transplantation . Study population : Children 0- 21 year receive liver transplantation . Informed consent : This obtain PI physician co-investigators . Randomization : Not applicable . Control group : Not applicable Test group : rATG pretreatment . 1 . Premedication acetaminophen 10 mg/kg orally + diphenhydramine 1 mg/kg intravenously + methylprednisolone 2 mg/kg , intravenously . 2. rATG 5 mg/kg initiate prior liver transplantation , half dose infuse least 4 hour , prior reperfusion liver graft . Total dose infuse 24 hour , less 8 hour . If requisite amount infuse LTx , continue LTx procedure afterward . Procedures : 1 . Tacrolimus initiate 0.01 mg per kg body weight orally . If biopsy-proven rejection occur , Tacrolimus titrate whole blood concentration : Month 1 12-15 ng/ml Months 2-3 8-12 ng/ml Month 4-6 5-8 ng/ml Months 6-12 &lt; 5 ng/ml 2 . This minimization protocol delay 3 month biopsy proven acute cellular rejection occur . For example , rejection occurs , Tacrolimus increase month 1 level 12-15 ng/ml , steroid add regimen . Steroids eliminate within 3 month rejection , Tacrolimus minimization resume describe . These protocol standard care event rejection , whether use rATG induction approach steroid-free Tacrolimus , Tacrolimus steroid . 3 . Laboratory test per clinical protocol . The clinical standard care follow perform post-LTx monitoring lab consist complete blood count differential count , serum sodium , potassium , chloride , bicarbonate , BUN , creatinine glucose , liver function test consist Total bilirubin , aspartate alanine transaminase ( ALT ) , aspartate glutamine transaminase ( AST ) , glutamyl galactosyl transaminase ( GGT ) , TAC whole blood concentration . These laboratory test perform least weekly first second month , twice monthly month 3 , monthly thereafter sixth month . The extra 5 ml need pharmacodynamic pharmacogenomic study discuss item 5 6 , Table 7 . 4 . Pharmacogenomic study consist characterize 100,000 SNPs use SNP array DNA extract 3 ml whole blood obtain pre-LTx , 80 child . 5 . Table 7 ( locate . Blood sample strategy : pharmacodynamic study measure lymphocyte subsetsas well dendritic cell type 1 2 show follow table ( table 8 ) . Concentration rATG also measure 0.1 ml human plasma obtain blood sample . Concentration associate half-maximal depletion subset determine pharmacodynamic model base Hill equation . This assay carry laboratory Dr. Rakesh Sindhi Rangos Research Center 530 45th St , Pittsburgh , Pa 15201 . Specimens store transplant laboratory indefinitely , control principal investigator , Dr. Rakesh Sindhi . The specimen store include assigned code number information link code number correspond subject ' identity keep separate , secure location . The specimen share secondary investigator without identifier . 6 . Liver biopsy perform per clinical standard care , rule acute cellular rejection . No protocol biopsy perform . 7 . The treatment rejection consist steroid taper per standard care . This standard include methylprednisolone , total dose 30 mg/kg , equivalent . If occurs , TAC whole blood concentration titrate start 12-15 ng/ml month 1 follow rejection event . Thereafter , time downward titration TAC concentration follow schema outline item 3 . 8 . Steroid-resistant rejection define biopsy-proven acute cellular rejection responsive methylprednisolone equivalent . 9 . Follow-up patient 12 month . 10 . All child receive standard care antiviral antipneumocystic prophylaxis</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Age 021 year , male female Primary OLTx , Whole/segmental , cadaveric/live , ReLTx , LTx set previous simultaneous kidney transplant . All child receive type LTx describe , conventional immunosuppression , enrol observational arm , treatment monitoring protocol . Multiorgan transplant ( liverintestine , liver intestine stomach organ ) Documented noncompliance Donor : Age &gt; 60 , macrovesicular steatosis &gt; 30 % , Hepatitis C B infection define antiHCV antibody positive , antiHepatitis B surface antigen Hepatitis B core antibody positive , malignancy , cold ischemia time &gt; 16 hour Children childbearing age receive pregnancy test time transplantation . Pregnancy contraindication liver transplantation therefore enrollment clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Rejection</keyword>
</DOC>